RxDoctor Payments Data

Qais Wahidi, MD

Internal Medicine · Folsom, CANPI 1699931097

Payments from drug & device makers

$4,826in general payments, 2019–2025

Across 251 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$894
  • AbbVie$675
  • Novo Nordisk$570
  • Pfizer$356
  • Lilly USA, LLC$299
  • Boehringer Ingelheim$207
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,826100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,826 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$741,440
Medicare patients
764
Services billed
11,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$145,396
JardianceEmpagliflozin82$117,260
MounjaroTirzepatide75$107,228
OzempicSemaglutide32$45,586
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$41,551
TrulicityDulaglutide15$33,597
XareltoRivaroxaban29$32,150
FarxigaDapagliflozin Propanediol27$29,382
ArexvyRsvpref3 Antigen/As01e/Pf69$21,829
JanuviaSitagliptin Phosphate14$18,497
ShingrixVaricella-Zoster Ge/As01b/Pf65$15,206
LinzessLinaclotide15$11,087
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$9,166
Atorvastatin Calcium746$8,995
Spiriva RespimatTiotropium Bromide17$8,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$356$145,396104 claims
Lilly USA, LLCMounjaro, Trulicity$299$140,82590 claims
Boehringer IngelheimJardiance, Spiriva Respimat$207$125,97499 claims
GSKTrelegy Ellipta, Arexvy, Shingrix, Arnuity Ellipta$894$82,753191 claims
Novo NordiskOzempic$570$45,58632 claims
Johnson & JohnsonXarelto$72$32,15029 claims
AstraZenecaFarxiga$145$29,38227 claims
MerckJanuvia$66$18,49714 claims
AbbVieLinzess$675$11,08715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Folsom

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →